Natalie Timoshin

On behalf of the editorial staff, I am very pleased to welcome Heidi Moawad, MD as the first ever Editor in Chief of 

Dr Moawad is a neurologist and Clinical Assistant Professor at Case Western Reserve University and John Carroll University in Cleveland, OH, where she teaches undergraduate and medical students. She is also a medical writer and content editor and has been writing about medical issues and health care careers for over 10 years. She is the author of 

Dr Moawad graduated from Case Western Reserve University School of Medicine and completed her neurology residency at The University of Chicago. When she is not working, she enjoys spending time with her husband and three kids. She also enjoys decorating and yoga.

As Editor in Chief, Dr Moawad will be heading a group of distinguished neurologists who serve as mentors for the editorial staff and who offer us ideas about topics we should consider covering. She has been a contributing author since the start of 

; we now look forward to working with her in her new role.

Articles

We are very pleased to welcome Heidi Moawad, MD as the first ever Editor in Chief of our journal, beginning February 1, 2019.

An Editor in Chief for Neurology Times

Slideshows

Presenting our year in review, a collection by experts in their respective fields of brain injury, MS, concussion, epilepsy, migraine, and more.

Neurology Times’ Top 11 Clinical Articles of 2018

You’ll want to get to bed early on Thursday, because you’ll have a very full week ahead. And even if you can't make #MDSCongress, October 5-9, 2018, get your highlights and Editor's Picks here.

Five Days in Hong Kong: The International Congress of Parkinson Disease and Movement Disorders

Parkinson disease articles published in 2018 reveal deeper dives into factors that include the impact of sleep and fatigue on symptoms.

Parkinson Disease: Recent Articles You May Have Missed

New Parkinson disease studies offer insights into topics such as LRRK2 G2019S transgene activity, preclinical drug development, and neuroprotection in Parkinson disease.

Parkinson Disease: Functional Assessment, Gene Disruptions, and More

Seven new drugs were approved for treatment of neurological disorders, including Parkinson disease, multiple sclerosis, and amyotrophic lateral sclerosis.

FDA Drug and Biologic Approvals for Neurology: 2017 Midyear Review

New studies shed light on topics such as nonencephalic pain and headache chronicity; benign childhood epilepsy with centrotemporal spikes and social cognition; and causal triggers of Alzheimer disease onset.